{"id":981021,"date":"2026-07-13T11:16:39","date_gmt":"2026-07-13T15:16:39","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ions-investor-alert-levi-korsinsky-notifies-investors-of-an-investigation-into-ionis-pharmaceuticals-ions\/"},"modified":"2026-07-13T11:16:39","modified_gmt":"2026-07-13T15:16:39","slug":"ions-investor-alert-levi-korsinsky-notifies-investors-of-an-investigation-into-ionis-pharmaceuticals-ions","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ions-investor-alert-levi-korsinsky-notifies-investors-of-an-investigation-into-ionis-pharmaceuticals-ions\/","title":{"rendered":"IONS Investor Alert: Levi &amp; Korsinsky Notifies Investors of an Investigation Into Ionis Pharmaceuticals (IONS)"},"content":{"rendered":"<p>        <!--body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p><b>IONS Investor Alert: Levi &amp; Korsinsky Notifies Investors of an Investigation Into Ionis Pharmaceuticals (IONS)<\/b><\/p>\n<p><i>Ionis Pharmaceuticals (NASDAQ: IONS) shareholders saw their holdings slide after the Phase-3 CARDIO-TTRansform trial missed its primary endpoint &#8212; and now have legal rights worth protecting. Levi &amp; Korsinsky is investigating.<\/i><\/p>\n<p>NEW YORK&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nShares of Ionis Pharmaceuticals fell more than 20% in the early trading on July 9, 2026, after the Company announced that its late-stage Phase-3 CARDIO-TTRansform trial, partnered with AstraZeneca, failed to meet its primary endpoint. If you purchased IONS securities and suffered a loss, you are encouraged to <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fzlk.com%2Fcases%2Fionis-pharmaceuticals-inc-class-action-lawsuit-ions%3Fprid%3D193007%26wire%3D2&amp;esheet=54568515&amp;newsitemid=20260713121445&amp;lan=en-US&amp;anchor=protect+your+shareholder+rights+now&amp;index=1&amp;md5=da2c9ce60aeea58b38e96c84b91d6681\">protect your shareholder rights now<\/a>. You may also contact Joseph E. Levi, Esq. via email at <a rel=\"nofollow\" href=\"mailto:jlevi@levikorsinsky.com\">jlevi@levikorsinsky.com<\/a> or by telephone at (212) 363-7500.<\/p>\n<p>\nThe CARDIO-TTRansform trial was designed to test whether the Company&#8217;s therapy could reduce combined cardiovascular death and recurrent events in patients with transthyretin-mediated amyloid cardiomyopathy. On July 9, 2026, the Company disclosed the trial did not meet that primary endpoint. The share price abruptly declined after the news was released.<\/p>\n<p>\nLevi &amp; Korsinsky is investigating potential securities law violations on behalf of IONS investors. The investigation focuses on whether the Company adequately disclosed the risks tied to the CARDIO-TTRansform program prior to the July 9, 2026 readout. Shareholders retain important legal rights, and those rights are best preserved by acting promptly.<\/p>\n<p>\nInvestors who purchased Ionis Pharmaceuticals shares and lost money are encouraged to <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fzlk.com%2Fcases%2Fionis-pharmaceuticals-inc-class-action-lawsuit-ions%3Fprid%3D193007%26wire%3D2&amp;esheet=54568515&amp;newsitemid=20260713121445&amp;lan=en-US&amp;anchor=submit+your+IONS+losses+for+review&amp;index=2&amp;md5=6008188bdb83411f6002d26cd22bd4b6\">submit your IONS losses for review<\/a>. You may also contact Joseph E. Levi, Esq. via email at <a rel=\"nofollow\" href=\"mailto:jlevi@levikorsinsky.com\">jlevi@levikorsinsky.com<\/a> or by telephone at (212) 363-7500.<\/p>\n<p><b>Levi &amp; Korsinsky, LLP<\/b> | Top 50 Securities Firm | (212) 363-7500 | <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.zlk.com&amp;esheet=54568515&amp;newsitemid=20260713121445&amp;lan=en-US&amp;anchor=www.zlk.com&amp;index=3&amp;md5=0b648abc8d5c02ece7df5e057857e42d\">www.zlk.com<\/a><\/p>\n<p>\nFrequently Asked Questions About the IONS Investigation<\/p>\n<p><b>Q: Who is eligible to participate in the IONS investigation?<\/b> A: Investors who purchased IONS stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses &#8212; not on whether you still hold the shares.<\/p>\n<p><b>Q: How much did IONS stock drop?<\/b> A: Shares fell over 20% after the Company disclosed that its Phase-3 CARDIO-TTRansform trial failed to meet its primary endpoint. Investors who purchased shares and suffered losses may be eligible to seek recovery.<\/p>\n<p><b>Q: What if I already sold my IONS shares &#8212; can I still recover losses?<\/b> A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought IONS and sold at a loss may still participate in the investigation.<\/p>\n<p><b>Q: What if my IONS losses are small &#8212; is it still worth contacting a lawyer?<\/b> A: Yes. There is no minimum loss amount required to participate in the investigation.<\/p>\n<p><b>Q: Do I need to go to court or give testimony?<\/b> A: No. Participating in the investigation does not require court appearances or depositions. If legal action is later pursued, the overwhelming majority of affected investors never appear in court either.<\/p>\n<p><b>Q: What does it cost me to participate?<\/b> A: There is no upfront cost to participate. Securities investigations and any resulting actions are generally handled on a contingency basis. No upfront fees, no retainer, and no out-of-pocket costs.<\/p>\n<p><b>Q: What if I live outside the United States?<\/b> A: U.S. securities fraud investigations generally cover purchases on U.S. exchanges regardless of the investor&#8217;s country of residence.<\/p>\n<p><b>Q: What do IONS investors need to do right now?<\/b> A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi &amp; Korsinsky for a free, no-obligation evaluation at <a rel=\"nofollow\" href=\"mailto:jlevi@levikorsinsky.com\">jlevi@levikorsinsky.com<\/a> or (212) 363-7500. No immediate action is required to remain eligible to participate in the investigation.<\/p>\n<p>\nAttorney Advertising. Prior results do not guarantee similar outcomes.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260713121445r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260713121445\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260713121445\/en\/<\/a><\/span><\/p>\n<p>\nLevi &amp; Korsinsky, LLP<br \/>\n<br \/>Joseph E. Levi, Esq.<br \/>\n<br \/>Ed Korsinsky, Esq.<br \/>\n<br \/>33 Whitehall Street, 27th Floor<br \/>\n<br \/>New York, NY 10004<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:jlevi@levikorsinsky.com\">jlevi@levikorsinsky.com<br \/>\n<\/a><br \/>Tel: (212) 363-7500<br \/>\n<br \/>Fax: (212) 363-7171<\/p>\n<p><b>KEYWORDS:<\/b> United States North America New York<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Class Action Lawsuit Professional Services Legal<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260713121445\/en\/2742089\/3\/Gradient_%28Square_Mark%29.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>IONS Investor Alert: Levi &amp; Korsinsky Notifies Investors of an Investigation Into Ionis Pharmaceuticals (IONS) Ionis Pharmaceuticals (NASDAQ: IONS) shareholders saw their holdings slide after the Phase-3 CARDIO-TTRansform trial missed its primary endpoint &#8212; and now have legal rights worth protecting. Levi &amp; Korsinsky is investigating. NEW YORK&#8211;(BUSINESS WIRE)&#8211; Shares of Ionis Pharmaceuticals fell more than 20% in the early trading on July 9, 2026, after the Company announced that its late-stage Phase-3 CARDIO-TTRansform trial, partnered with AstraZeneca, failed to meet its primary endpoint. If you purchased IONS securities and suffered a loss, you are encouraged to protect your shareholder rights now. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ions-investor-alert-levi-korsinsky-notifies-investors-of-an-investigation-into-ionis-pharmaceuticals-ions\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;IONS Investor Alert: Levi &amp; Korsinsky Notifies Investors of an Investigation Into Ionis Pharmaceuticals (IONS)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-981021","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>IONS Investor Alert: Levi &amp; Korsinsky Notifies Investors of an Investigation Into Ionis Pharmaceuticals (IONS) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ions-investor-alert-levi-korsinsky-notifies-investors-of-an-investigation-into-ionis-pharmaceuticals-ions\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IONS Investor Alert: Levi &amp; Korsinsky Notifies Investors of an Investigation Into Ionis Pharmaceuticals (IONS) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"IONS Investor Alert: Levi &amp; Korsinsky Notifies Investors of an Investigation Into Ionis Pharmaceuticals (IONS) Ionis Pharmaceuticals (NASDAQ: IONS) shareholders saw their holdings slide after the Phase-3 CARDIO-TTRansform trial missed its primary endpoint &#8212; and now have legal rights worth protecting. Levi &amp; Korsinsky is investigating. NEW YORK&#8211;(BUSINESS WIRE)&#8211; Shares of Ionis Pharmaceuticals fell more than 20% in the early trading on July 9, 2026, after the Company announced that its late-stage Phase-3 CARDIO-TTRansform trial, partnered with AstraZeneca, failed to meet its primary endpoint. If you purchased IONS securities and suffered a loss, you are encouraged to protect your shareholder rights now. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. &hellip; Continue reading &quot;IONS Investor Alert: Levi &amp; Korsinsky Notifies Investors of an Investigation Into Ionis Pharmaceuticals (IONS)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ions-investor-alert-levi-korsinsky-notifies-investors-of-an-investigation-into-ionis-pharmaceuticals-ions\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-13T15:16:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260713121445r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ions-investor-alert-levi-korsinsky-notifies-investors-of-an-investigation-into-ionis-pharmaceuticals-ions\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ions-investor-alert-levi-korsinsky-notifies-investors-of-an-investigation-into-ionis-pharmaceuticals-ions\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"IONS Investor Alert: Levi &amp; Korsinsky Notifies Investors of an Investigation Into Ionis Pharmaceuticals (IONS)\",\"datePublished\":\"2026-07-13T15:16:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ions-investor-alert-levi-korsinsky-notifies-investors-of-an-investigation-into-ionis-pharmaceuticals-ions\\\/\"},\"wordCount\":667,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ions-investor-alert-levi-korsinsky-notifies-investors-of-an-investigation-into-ionis-pharmaceuticals-ions\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260713121445r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ions-investor-alert-levi-korsinsky-notifies-investors-of-an-investigation-into-ionis-pharmaceuticals-ions\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ions-investor-alert-levi-korsinsky-notifies-investors-of-an-investigation-into-ionis-pharmaceuticals-ions\\\/\",\"name\":\"IONS Investor Alert: Levi &amp; Korsinsky Notifies Investors of an Investigation Into Ionis Pharmaceuticals (IONS) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ions-investor-alert-levi-korsinsky-notifies-investors-of-an-investigation-into-ionis-pharmaceuticals-ions\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ions-investor-alert-levi-korsinsky-notifies-investors-of-an-investigation-into-ionis-pharmaceuticals-ions\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260713121445r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-07-13T15:16:39+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ions-investor-alert-levi-korsinsky-notifies-investors-of-an-investigation-into-ionis-pharmaceuticals-ions\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ions-investor-alert-levi-korsinsky-notifies-investors-of-an-investigation-into-ionis-pharmaceuticals-ions\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ions-investor-alert-levi-korsinsky-notifies-investors-of-an-investigation-into-ionis-pharmaceuticals-ions\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260713121445r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260713121445r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ions-investor-alert-levi-korsinsky-notifies-investors-of-an-investigation-into-ionis-pharmaceuticals-ions\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IONS Investor Alert: Levi &amp; Korsinsky Notifies Investors of an Investigation Into Ionis Pharmaceuticals (IONS)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IONS Investor Alert: Levi &amp; Korsinsky Notifies Investors of an Investigation Into Ionis Pharmaceuticals (IONS) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ions-investor-alert-levi-korsinsky-notifies-investors-of-an-investigation-into-ionis-pharmaceuticals-ions\/","og_locale":"en_US","og_type":"article","og_title":"IONS Investor Alert: Levi &amp; Korsinsky Notifies Investors of an Investigation Into Ionis Pharmaceuticals (IONS) - Market Newsdesk","og_description":"IONS Investor Alert: Levi &amp; Korsinsky Notifies Investors of an Investigation Into Ionis Pharmaceuticals (IONS) Ionis Pharmaceuticals (NASDAQ: IONS) shareholders saw their holdings slide after the Phase-3 CARDIO-TTRansform trial missed its primary endpoint &#8212; and now have legal rights worth protecting. Levi &amp; Korsinsky is investigating. NEW YORK&#8211;(BUSINESS WIRE)&#8211; Shares of Ionis Pharmaceuticals fell more than 20% in the early trading on July 9, 2026, after the Company announced that its late-stage Phase-3 CARDIO-TTRansform trial, partnered with AstraZeneca, failed to meet its primary endpoint. If you purchased IONS securities and suffered a loss, you are encouraged to protect your shareholder rights now. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. &hellip; Continue reading \"IONS Investor Alert: Levi &amp; Korsinsky Notifies Investors of an Investigation Into Ionis Pharmaceuticals (IONS)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ions-investor-alert-levi-korsinsky-notifies-investors-of-an-investigation-into-ionis-pharmaceuticals-ions\/","og_site_name":"Market Newsdesk","article_published_time":"2026-07-13T15:16:39+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260713121445r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ions-investor-alert-levi-korsinsky-notifies-investors-of-an-investigation-into-ionis-pharmaceuticals-ions\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ions-investor-alert-levi-korsinsky-notifies-investors-of-an-investigation-into-ionis-pharmaceuticals-ions\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"IONS Investor Alert: Levi &amp; Korsinsky Notifies Investors of an Investigation Into Ionis Pharmaceuticals (IONS)","datePublished":"2026-07-13T15:16:39+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ions-investor-alert-levi-korsinsky-notifies-investors-of-an-investigation-into-ionis-pharmaceuticals-ions\/"},"wordCount":667,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ions-investor-alert-levi-korsinsky-notifies-investors-of-an-investigation-into-ionis-pharmaceuticals-ions\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260713121445r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ions-investor-alert-levi-korsinsky-notifies-investors-of-an-investigation-into-ionis-pharmaceuticals-ions\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ions-investor-alert-levi-korsinsky-notifies-investors-of-an-investigation-into-ionis-pharmaceuticals-ions\/","name":"IONS Investor Alert: Levi &amp; Korsinsky Notifies Investors of an Investigation Into Ionis Pharmaceuticals (IONS) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ions-investor-alert-levi-korsinsky-notifies-investors-of-an-investigation-into-ionis-pharmaceuticals-ions\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ions-investor-alert-levi-korsinsky-notifies-investors-of-an-investigation-into-ionis-pharmaceuticals-ions\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260713121445r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-07-13T15:16:39+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ions-investor-alert-levi-korsinsky-notifies-investors-of-an-investigation-into-ionis-pharmaceuticals-ions\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ions-investor-alert-levi-korsinsky-notifies-investors-of-an-investigation-into-ionis-pharmaceuticals-ions\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ions-investor-alert-levi-korsinsky-notifies-investors-of-an-investigation-into-ionis-pharmaceuticals-ions\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260713121445r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260713121445r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ions-investor-alert-levi-korsinsky-notifies-investors-of-an-investigation-into-ionis-pharmaceuticals-ions\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"IONS Investor Alert: Levi &amp; Korsinsky Notifies Investors of an Investigation Into Ionis Pharmaceuticals (IONS)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/981021","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=981021"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/981021\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=981021"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=981021"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=981021"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}